Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy

<div>Treatment course and efficacy of 12 weeks of TVR/PegIFN/RBV triple therapy and 36 weeks of consecutive PegIFN/RBV dual therapy.</div>

Hepatitis Research and Treatment

fig1

Figure 1

Figure 1: Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy 

Figure 1 | Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy 